IN THE NEWS
Japan’s Sosei allies with ex-Novartis team to develop neurological drug pipeline
TOKYO [Reuters] – Novartis’ former CEO Joe Jimenez and NIBR head Mark Fishman believe that pairing digital technology with drug development in large underserved indications can provide a solid investment model and expedite the creation of medicines in disease areas that have been all but abandoned by their former peer pharma companies.
Together with co-founder Paul Sekhri, president and CEO of eGenesis Inc., they created investment firm Aditum Bio in 2019. Sekhri — a veteran executive of Novartis AG (NYSE:NVS; SIX:NOVN) himself — is remaining at eGenesis.
Jimenez led Novartis from 2010 until January 2018. Fishman was the founding president of the Novartis Institutes of BioMedical Research from from 2002-16. At Aditum, Jimenez is co-founder and managing director, and Fishman is co-founder and chair of the SAB.